15 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
TTWO Take-Two Interactive Software, Inc. $131.48 $14.97B N/A
Article Searches
Takeda Pharmaceutical Co. Ltd (TAK) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4301840-takeda-pharmaceutical-co-ltd-tak-ceo-christophe-weber-on-q3-2019-results-earnings-call?source=feed_tag_japan Nov 02, 2019 - Takeda Pharmaceutical Co. Ltd. (NYSE:TAK) Q3 2019 Results Earnings Conference Call October 31, 2019 08:00 AM ET Company Participants Takashi Okubo - IR Christophe Weber - CEO Constantine Saroukos - CF
Takeda Pharmaceutical Co. Ltd (TAK) CEO Christophe Weber on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4301840-takeda-pharmaceutical-co-ltd-tak-ceo-christophe-weber-q3-2019-results-earnings-call?source=feed_tag_japan Nov 02, 2019 - Takeda Pharmaceutical Co. Ltd. (NYSE:TAK) Q3 2019 Results Earnings Conference Call October 31, 2019 08:00 AM ET Company Participants Takashi Okubo - IR Christophe Weber - CEO Constantine Saroukos - CF
Seattle Genetics (SGEN) Q3 Loss Widens, Revenues Top Mark http://www.zacks.com/stock/news/593607/seattle-genetics-sgen-q3-loss-widens-revenues-top-mark?cid=CS-ZC-FT-analyst_blog|earnings_article-593607 Oct 30, 2019 - Seattle Genetics (SGEN) incurs wider-than-expected loss in third-quarter 2019 but rides high on revenue beat.
Takeda down 2% on underwhelming TAK-788 data https://seekingalpha.com/news/3464620-takeda-2-percent-underwhelming-takminus-788-data?source=feed_news_all May 16, 2019 - Investors appear unmoved with interim data from an open-label Phase 1/2 clinical trial evaluating Takeda's (TAK -2.4%) oral TKI inhibitor TAK-788 in non-small cell lung cancer (NSCLC) patients
What's in the Cards for Sunesis (SNSS) This Earnings Season? http://www.zacks.com/stock/news/406478/whats-in-the-cards-for-sunesis-snss-this-earnings-season?cid=CS-ZC-FT-406478 May 01, 2019 - Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark http://www.zacks.com/stock/news/404524/seattle-genetics-sgen-q1-loss-narrows-revenues-top-mark?cid=CS-ZC-FT-404524 Apr 26, 2019 - Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.
Kamada to Begin Phase III Study for Inhaled AAT Product in 2H http://www.zacks.com/stock/news/384736/kamada-to-begin-phase-iii-study-for-inhaled-aat-product-in-2h?cid=CS-ZC-FT-384736 Apr 17, 2019 - Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
Company News For Mar 5, 2019 http://www.zacks.com/stock/news/357738/company-news-for-mar-5-2019?cid=CS-ZC--357738 Mar 05, 2019 - Companies in the news are; PLCE, BIIB, NITE, ASND and TAK
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff http://www.zacks.com/stock/news/346023/ironwood-to-get-new-ceo-current-ceo-to-head-latest-spinoff?cid=CS-ZC-FT-346023 Jan 07, 2019 - Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.
Takeda and Ovid Therapeutics expand clinical program for TAK-935/OV935 https://seekingalpha.com/news/3370995-takeda-ovid-therapeutics-expand-clinical-program-takminus-935-ov935?source=feed_news_all Jul 18, 2018 - Takeda Pharmaceutical (OTCPK:TKPYY) and Ovid Therapeutics (NASDAQ:OVID) will expand their TAK-935/OV935 clinical development program to include three clinical trials:Phase 2 ARCADE: A multicenter

Pages: 12

Page 1